2020Tiew PY, Poh ME, Chotirmall SH, et al. Environmental fungal sensitisation associates with poorer clinical outcomes in COPD. European Respiratory Journal 2020. DOI: 10.1183/13993003.00418-2020
2020Tiew PY, Poh ME, Chotirmall SH, et al. 'High risk' clinical and inflammatory clusters in COPD of Chinese descent. Chest 2020; 158: 145-156.
2020Chai CS, Liam CK, Poh ME, et al. Predictors of acquired T790M Mutation in patients failing first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer Management and Research 2020 12: 5439-5450.
2019Liam CK, Liam YS, Poh ME, et al. Accuracy of lung cancer staging in the multidiscplinary team setting. Transl Lung Cancer Res 2019. DOI: 10.21037/tlcr.2019.11.28
2019Poh ME, Liam CK, Mun KS, et al. Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy. Thoracic Cancer 2019; 10: 1841-1845.
2019Liam CK, Poh ME, Liam YS. Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. J Thorac Dis 2019; 11: 1847-1851.
2018Poh ME, Liam CK, Rajadurai P, Chai CS. Epithelial-to-Mesenchymal Transition (EMT) Causing Acquired Resistance to Afatinib in a Patient with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma (Manuscript ID: JTD-18-141) (Accepted for publication by Journal of Thoracic Disease on 19 June 2018) (ISI-Indexed)
2017Chai CS, Liam CK, Poh ME et al.(2017). Epidermal growth factor receptor mutation in newly diagnosed lung adenocarcinoma. J Respir Med Lung Dis; 2(2): 1016. (ISI-Indexed)
2016Chai CS, Liam CK, Poh ME, et al. (2016). Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients. European Respiratory Journal. 48 (suppl 60) :PA4840. (ISI-Indexed)
2016Chai CS, Liam CK, Poh ME, et al.(2016). Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma. European Respiratory Journal; 48 (suppl 60) : OA3341 (ISI-Indexed)
2015Chai CS, Liam CK, Poh ME, et al. (2015). Treatment outcome of Malaysian patients with advanced lung adenocarcinoma. Annals of Oncology. 26 (Supplement 9): ix 125 – ix 1457 (ISI-Indexed)
2014Poh, M. E., Liam, C. K., Ng, K. P., Tan, R. X. 2014. Mycobacterium Brisbanense Species Nova Isolated From a Patient With Chronic Cavitary Lung Infection Chest. (Tier 1, Impact Factor = 7.132) (ISI-Indexed)
201420.Liam CK, Pang YK and Poh ME. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 2014; 9(9):e70-1 (ISI-Indexed)
201421.Poh ME, Liam CK, Tan JL, et al. Acrometastasis from an epidermal- growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma. Cancer Treatment Communications. 2014; Volume 2 (Issues 2-3):21-23 (SCOPUS-Indexed)
2013Liam CK, Poh ME, Pang YK et al. Advanced right lung adenocarcinoma with ipsilateral breast metastasis. Respirology Case Report. 2013; 1(1):20- 22 (ISI-Indexed)
2013Poh ME, Liam CK, Pang YK, et al. Endobronchial metastases from resected renal cell carcinoma causing total lung collapse. Respirology Case Report. 2013; 1(2):26-7 (ISI-Indexed)
2007Sim BLH, Nissapatorn V, Poh ME, et al. Toxoplasmosis: a silent opportunistic diseases in HIV/AIDS patients. Research Journal of Parasitology. 2007; 2(1):23-31 (ISI-Indexed)